

pdmonitor[®]



scan to
learn more

*Standing by you,
at every move
you make*



A non-invasive continuous monitoring system,
for patients with Parkinson's disease

powered by



pd neurotechnology[®]
medical solutions

www.pdneurotechnology.com

Who we are

PD Neurotechnology® is a high tech, medical device company founded in 2015 by a team of experts in patient monitoring systems for movement disorders. Our team has developed an innovative, non-invasive, continuous monitoring medical device and a sophisticated expert system. **PD Neurotechnology®** has been certified with **ISO 9001:2015, ISO 27001:2013 and ISO 13485:2016**.



Our Product


Our first product - **PDMonitor®** - is a medical device for monitoring Parkinson's disease, through the application of sensors, wireless technology and machine learning algorithms.

PDMonitor® can trace, record and process a variety of symptoms commonly present in the disease course.

The product comprises five lightweight devices worn on different body parts, a docking station and the cloud where patient's data is securely stored.

A mobile app and a web-based physician tool facilitate patient-physician interaction, improve clinical decision-making and enhance overall patient experience.

In June 2019, **PDMonitor®** was certified as a Class IIa medical device according to Directive 93/42/EEC.



Parkinson's disease (PD) is the second most common neurodegenerative disease and one of the main factors causing disability around the world [1]. From 1990 to 2017, the worldwide estimated prevalence of PD grew by 200% and reached 8.5 million [1]. Projections show that the population of PD patients will be well over 14 million by 2040 [2]. In Europe, prevalence and incidence rates for PD are estimated at approximately 108-257/100,000 and 11-19/100,000 per year, respectively [3].

[1] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Global Health Metrics* 2018; 392(10159): 1789-1858. [2] Dorsey E R, Bloem B R. The Parkinson Pandemic-A Call to Action. *JAMA Neurol.* 2018; 75(1): 9-10. [3] Balestrino R, Schapira A H V. Parkinson disease. *European Journal of Neurology* 2020, 27: 27–42.